Gilead Sciences
UAB Drug Remdesivir Is First to Block the COVID-19 Virus, May Become Standard of Care. Fauci “Optimistic.”
Remdesivir, a drug developed through a federal grant to UAB, may be the first effective therapy for treating severely ill COVID-19 patients, early analysis of a large federally sponsored study found this week.
World Awaits Results Of COVID-19 Drug Treatment Developed At UAB Center
In the search for a drug treatment for COVID-19, prime interest has centered on Remdesivir, a compound produced by Gilead Sciences that has its roots in a National Institutes of Health-funded center based at UAB.
UAB Leads a New Anti-Viral Drug Trial to Combat the Coronavirus
The University of Alabama at Birmingham is leading a new anti-viral drug trial in Wuhan, China to combat the coronavirus outbreak.
